中科藍訊(688332.SH):擬向銀行申請總額不超15億元綜合授信額度
格隆匯2月6日丨中科藍訊(688332.SH)公佈,公司於2023年2月6日召開第二屆董事會第三次會議,審議通過了《關於公司2023年度向銀行申請綜合授信額度的議案》。
結合實際發展需要,公司擬向銀行申請總額不超過人民幣15億元的綜合授信額度,授信業務包括但不限於短期流動資金貸款、項目貸款、中長期借款、銀行承兑匯票、保函等。具體授信業務品種、額度和期限,以銀行最終核定為準。在授信期限內,授信額度可循環使用,可以在不同銀行間進行調整。授信額度有效期為公司2023年第二次臨時股東大會審議通過之日起至公司2023年度股東大會召開之日止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.